In this retrospective study, we compared the effectiveness and safety of adjuvant alectinib and adjuvant chemotherapy in 68 ALK-TKI-naive patients with completely resected ALK-positive, stage IB to IIIB NSCLC. Here, ALK is linked to non-small cell lung carcinoma.